<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>H19 and insulin-like growth factor II (IGF2) are among a few genes which have been confirmed to be imprinted in <z:mpath ids='MPATH_458'>normal</z:mpath> human embryonal tissues </plain></SENT>
<SENT sid="1" pm="."><plain>This results in monoallelic expression of maternal H19 and paternal IGF2 </plain></SENT>
<SENT sid="2" pm="."><plain>Loss of imprinting of these genes producing biallelic expression has been observed in <z:hpo ids='HP_0002667'>Wilm's tumor</z:hpo> and <z:hpo ids='HP_0006743'>embryonal rhabdomyosarcoma</z:hpo>, suggesting that an epigenetic change of DNA, in addition to a genetic change in oncogene(s) and/or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene(s), may be involved in the development of these <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003006'>Neuroblastoma</z:hpo>, which is an <z:e sem="disease" ids="C0027654" disease_type="Neoplastic Process" abbrv="">embryonal tumor</z:e> originating from neural crest-derived cells, occasionally occurs in individuals with the <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e>; <z:hpo ids='HP_0002667'>Wilm's tumor</z:hpo> and <z:hpo ids='HP_0006743'>embryonal rhabdomyosarcoma</z:hpo> occur even more frequently in the <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e>; and paternal <z:mp ids='MP_0008867'>uniparental disomy</z:mp> of H19 and IGF2 loci (chromosome 11p15) is present in the <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> cell lines express IGF2, and autocrine/paracrine effects of IGF2 have been demonstrated in these cells </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, we examined for imprinting of both H19 and IGF2 in primary untreated <z:hpo ids='HP_0003006'>neuroblastomas</z:hpo> using the RsaI and ApaI polymorphisms within these genes, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Seven of 15 tumors were informative for H19 and for IGF2, and <z:hpo ids='HP_0000001'>all</z:hpo> of these cases showed monoallelic expression of both of these genes </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that loss of imprinting of H19 and IGF2 does not occur in <z:hpo ids='HP_0003006'>neuroblastomas</z:hpo> </plain></SENT>
</text></document>